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INTRODUCTION
In 1981 the “Patient Registry for the Characterization of Primary Pulmonary Hypertension” was set up,
supported by the National Heart, Lung and Blood Institute, and recruited 194 patients across
32 clinical centres over 4 years in the United States1,2. The estimated median survival of these incident
cases of primary pulmonary hypertension (which approximates to what we would now term idiopathic
pulmonary arterial hypertension, IPAH) was 2.8 years, with a 68% survival rate at 1 year, 48% at 3 years
and 35% at 5 years1.
Since 2000 a number of national registries have been set-up across the world to study the
developing epidemiology of pulmonary arterial hypertension (PAH)3. The largest of these is the
REVEAL (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease
Management) Registry in the United States4. Between 2006 and 2009, 2635 prevalent and incident
cases were included in survival analysis across 55 centres. For IPAH, there was a 91% survival rate
at 1 year, 74% at 3 years and 65% at 5 years4. The Spanish registry also recruited 866 prevalent
and incident cases of IPAH between 2007 and 2008 and calculated 1-, 3- and 5-year survival rates
of 87%, 75% and 65% respectively5. In the French registry, which also analysed prevalent and
incident cases, for a sub-population of 190 patients with IPAH, hereditary PAH (HPAH) and
anorexigen-associated PAH cases (which all have similar baseline characteristics and outcomes)
between 2002 and 2003, a 1-year survival rate of 83% and 3-year of 58% was calculated6,7.
In the UK there was a focus on incident cases, and 482 patients with IPAH, HPAH, and
anorexigen-associated PAH were included between 2001 and 2009 and had 1-, 3- and 5-year
survival rates of 93%, 73% and 61% respectively8. Although there is debate about the inclusion
of both prevalent and incident cases in these registries (owing to survivor bias), there is broad
agreement over current survival rates across these registries.
Measurable progress has been made in the management of pulmonary arterial hypertension
over the last 33 years – now, at 5 years, a larger proportion of people are living with the disease,
rather than dying from it. In this review article we take a historical approach to reflect on the
journey that has brought us to where we are today, focussing on the key milestones in the
management of pulmonary arterial hypertension, signposted by the World Health Organisation
(WHO) “World Symposia in Pulmonary Hypertension”. It will become apparent that this mirrors
the developments and movements in medicine over the last 150 years: from pathology to
physiology, from physiology to pharmacology, from pharmacology to cell biology, from cell
biology to genetics9.
THE FIRST AGE: PATHOLOGY
The discovery of the pulmonary circulation has recently been reviewed in this journal10. It began
with the rejection of Galen’s and Ibn Sina’s (Avicenna’s) longstanding doctrine, that the liver
Cite this article as: Chakrabarti AM, Mitchell JA, Wort SJ. Progress in the understanding and
management of pulmonary arterial hypertension, Global Cardiology Science and Practice 2015:13
http://dx.doi.org/10.5339/gcsp.2015.13
http://dx.doi.org/
10.5339/gcsp.2015.13
Submitted: 03 December 2014
Accepted: 26 February 2015
ª 2015 Chakrabarti, Mitchell, Wort,
licensee Bloomsbury Qatar
Foundation Journals. This is an open
access article distributed under the
terms of the Creative Commons
Attribution license CC BY 4.0, which
permits unrestricted use,
distribution and reproduction in any
medium, provided the original work
is properly cited.
1Royal Brompton Hospital, London, UK
2National Heart and Lung Institute,
Imperial College London, UK
3Royal Brompton Hospital and National
Heart and Lung Institute, Imperial
College London, UK
*Email: s.wort@imperial.ac.uk
produced blood which was infused with air from the lungs and heat from the heart before being
evaporated or consumed by the other organs in the body10. Ibn Al-Nafis (1213-1288) in the Arab
world and Michael Servetus (1511-1553) and Realdus Colombus (1516-1559) in the European world
postulated a pulmonary circulation as we understand it today11. This laid the foundation for the
discovery of the “motion of the heart” and the circulation of blood by William Harvey (1578-1657)
and the pulmonary capillaries by Marcello Malpighi (1628-1694).
The first documented clinical case reports of pulmonary hypertension come two centuries later
from Germany. In 1865, Klob found narrowing of the finer branches of the pulmonary artery in a
patient who had died with progressive ankle oedema, dyspnoea and cyanosis12,13. In 1891, von
Romberg wrote about a 24-year-old patient with a similar clinical course in whom, on autopsy, he
described “pulmonary vascular sclerosis” in addition to massive right ventricular hypertrophy14.
The first clinical case series of pulmonary hypertension came from Argentina. Ayerza had
described a patient with a chronic productive cough, dyspnoea, severe cyanosis and right heart
failure in 1901 which he termed ‘cardı´aco negro’ (black heart) due to the significant cyanosis15.
His student Arrillaga published a series of 11 cases in 1913 as his doctoral thesis and the disease
became known as Ayerza’s disease16. Many cases were subsequently reported across the world.
The aetiology of these lesions remained unclear and although syphilis was postulated, Brenner
disproved this after studying the pathology of 100 cases in the United States17. He interpreted
“his pathological findings as morphologic evidence of chronic pulmonary disease, moderate
pulmonary atherosclerosis and right ventricular hypertrophy”18. However, understanding of
the relationship between the pulmonary and cardiac pathology could only come with
physiological analysis.
THE SECOND AGE: PHYSIOLOGY
In Germany in 1929, Forssmann introduced a catheter into his own right heart under fluoroscopic
guidance19. Although rejected by his peers at the time, right heart catheterisation was taken up
and refined in the United States by Cournand20,21 and Richards22,23 particularly as a means of
measuring cardiac output and also pulmonary haemodynamics. The three were jointly awarded
the Nobel Prize in Physiology or Medicine in 1956 “for their discoveries concerning heart
catheteri[s]ation and pathological changes in the circulatory system”. Dresdale first coined the
term ‘primary pulmonary hypertension’ in his paper from 1951 to describe patients with isolated
elevated pulmonary artery pressures with an elevated right atrial pressure and decreased cardiac
output24. Wood, working in the United Kingdom, investigated pulmonary hypertension extensively
using cardiac catheterisation25. He related the physiological analysis to patient symptoms. With
this mechanistic analysis, he developed a classification of pulmonary hypertension, including now
familiar categories, such as thromboembolic disease, cor pulmonale, congenital cardiac defects,
and idiopathic or primary PH. Much work was done detailing the physiological responses of the
pulmonary circulation, with the notable discovery of hypoxic vasoconstriction9. Drugs started
to be used to probe the pulmonary circulation with the demonstration that both tolazoline
(an alpha-adrenergic receptor antagonist and pulmonary and systemic vasodilator)26 delivered
intravenously and acetylcholine27 delivered to the pulmonary artery could acutely reduce
pulmonary artery pressures, but there were still no treatments developed for primary pulmonary
hypertension.
However, in the report, the chapter on prognosis and treatment concludes, “once established,
primary pulmonary hypertension is almost always fatal . . . While a number of vasoactive drugs have
been found to lower the pulmonary arterial pressure in acute studies, prolonged therapy has been
found quite ineffective . . . No effective therapy is known”.28
THE THIRD AGE: PHARMACOLOGY AND CELL BIOLOGY
The first treatment to successfully extend the survival of patients with pulmonary hypertension
was not a drug therapy, but in fact heart-lung transplantation31. As understanding of the
pharmacology grew, drugs that were already available at the time were used to try to treat the
disease.
Attempts were made to reduce the pulmonary artery pressure and pulmonary vascular resistance
using drugs that were available. Rich and Brundage found that in a subset of patients high-dose
calcium channel blockers (up to 720mg/day of diltiazem or 240mg/day of nifedipine) could achieve
Page 2 of 13
Chakrabarti, Mitchell and Wort. Global Cardiology Science and Practice 2015:13
this in a sustainable manner32. At their one-year follow up they also noted regression of the right
ventricular hypertrophy on echocardiography. Further study showed that at 5 years there was a
significant benefit on survival as compared to those patients who did not respond to calcium channel
blockade – 94% of the responders were alive, compared to 55% of the non-responders33. Interestingly,
they also anticoagulated patients on the basis of non-uniform pulmonary blood flow radiographically.
Unfortunately, it was still only a minority of patients that had a vasodilator response and could
therefore be treated with calcium channel blockade.
Warfarin was given to 47% of responders and 57% of non-responders and was found to be
associated with an improved survival33. Other, retrospective studies supported the theory that warfarin
improved survival and so its use was recommended34,35. (The database of the Comparative,
Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) has recently
been analysed to assess the question of anticoagulation in PAH36. Although there were limitations in
the data in this observational study, particularly with levels of anticoagulation and the percentage of
patients in the anticoagulation group not on anticoagulation for the entire observation period, they did
note a statistically significant survival advantage in those patients with IPAH on warfarin).
In 1976, Vane’s group isolated an enzyme from arteries that transformed prostaglandin-G2 or H2 to
an unstable substance “prostaglandin-X” that inhibited platelet aggregation and relax certain blood
vessels37. This new metabolite was termed prostaglandin-I2 or prostacyclin and found to be a
potent pulmonary vasodilator in the cat and monkey38. More importantly, with respect to a therapeutic
use in pulmonary hypertension, there was less effect on cardiac output and aortic pressure (i.e. the
systemic circulation)38. Vane went on to share the Nobel Prize for Physiology or Medicine in 1982 with
Bergstro¨m and Samuelsson “for their discoveries concerning prostaglandins and related biologically
active substances”.
The proof of principle study was undertaken in 1982 on 7 patients with primary pulmonary
hypertension39. Intravenous prostacyclin was administered with an incremental dose escalation with
measurements of pulmonary artery pressure by right heart catheter as each increase. There was a
dose-dependent reduction in the pulmonary vascular resistance with a maintained systolic blood
pressure and an increase in cardiac output. The infusion was maintained for 24-48 hours in three
patients; in these the reduction in pulmonary vascular resistance was sustained for the duration of
the infusion.
In the meantime, many patients were dying whilst awaiting a transplant. In the UK, a continuous
infusion of prostacyclin was set up through a subcutaneously tunnelled line using a syringe pump in a
young woman who was bed-bound with severe pulmonary hypertension40. She responded with a fall in
pulmonary vascular resistance, improved oxygenation and a rise in exercise tolerance. The infusion
had been running for 13 months at the time of publication in 1984 and she was living independently
at home.
The First World Symposium, Geneva, 1973
The World Health Organisation convened a meeting in Geneva in 1973 to “review the hitherto
scattered scientific information and to discuss the [a]etiology and pathogenesis,
pathophysiology, morphology, clinical patterns, clinical physiology, and epidemiology of primary
pulmonary hypertension”28. This was in response to a 20-fold increase in cases of pulmonary
hypertension that was reported in 1968 in Switzerland29. Further study had identified an
epidemic across Austria, Germany and Switzerland that had started in 1967, peaked in 1968-9
and disappeared after 197230. Although it was not possible to prove causation, there was both
temporal and geographical association between these cases and the marketing of aminorex,
an appetite suppressant that was available in those countries from 1965 and subsequently
withdrawn in 1968.
In addition to raising the profile of this orphan disease, the 1st WHO meeting created the
definition of PH that we use today with a mean pulmonary artery pressure, as measured by right
heart catheterisation, exceeding 25 mm Hg indicating hypertension28. The pulmonary wedge
pressure was normal in the primary form. The meeting also classified pulmonary hypertension into
primary, that is “pulmonary hypertension of unknown cause”28 and secondary and focussed on the
primary form. It also recommended establishing a central register, the fruits of which were
described at the beginning of this article.
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Subsequent studies showed that the haemodynamic improvement could be maintained with
continuous prostacyclin infusions in a cohort of patients (although there was a need for dose
escalation)41. The first randomised controlled trial in pulmonary hypertension compared continuous
intravenous prostacyclin with conventional therapy42. They recruited 81 patients with severe primary
pulmonary hypertension in New York Heart Association (NYHA) classes III or IV. As well as physiological
markers confirming a significant improvement in haemodynamics, functional tests showed a
statistically and physiologically significant improvement in six-minute walk test distance. Most
impressively, there was a significant difference in survival – all 8 deaths had occurred in the
conventional treatment arm. To date, no other randomised controlled trial of any agent in pulmonary
hypertension has demonstrated a pure survival benefit. Finally, there was proof of a successful
treatment in all patients with primary pulmonary hypertension. The US Food and Drug Administration
(FDA) approved its use in 1995.
However, the use of continuous intravenous epoprostenol was not without complications. In the
original study there were frequent minor side effects, but more importantly there were serious
complications most often due to the delivery system including line sepsis, thrombotic events, and
malfunctions of the drug delivery system resulting in interruptions to the infusion42. Furthermore, drug
preparation and the need to carry a syringe pump all add to the difficulties of managing a continuous
prostacyclin infusion at home. An effective subcutaneous prostacyclin analogue, treprostinil, was
successfully developed, which was easier to use, but still necessitated a continuous infusion44. Inhaled
iloprost (another, longer-acting, prostacyclin analogue) was evaluated as an alternative to continuous
intravenous infusions, and although there were sustained improvements in exercise capacity,
pulmonary haemodynamics and clinical effectiveness, the nebulised iloprost was given every two to
three hours without interruption of bed rest at night45,46. Treatments that were more straightforward to
administer, such as oral treatments, were clearly needed.
Due to the availability of pulmonary hypertension lung tissue from patients who had undergone
transplant and the advancement in cell biology techniques, there was a significant advance in
understanding the vascular biology of the pulmonary artery. In particular the pathways and agents
controlling vasoconstriction and vasodilatationwere explored and identified, including endothelin-1 (ET-1)
and nitric oxide (NO). This understanding still forms the basis for all the treatment options available today.
Table 1. WHO functional class (from Rich, 1998)43.
Functional class Symptoms
I Patients with pulmonary hypertension but without resulting limitation of physical activity.
Ordinary physical activity does not cause undue dyspnea or fatigue,
chest pain or near syncope.
II Patients with pulmonary hypertension resulting in slight limitation of physical activity.
They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue,
chest pain or near syncope.
III Patients with pulmonary hypertension resulting in marked limitation of physical activity.
They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue,
chest pain or near syncope.
IV Patients with pulmonary hypertension with inability to carry out any physical activity
without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or
fatigue may even be present at rest. Discomfort is increased by any physical activity.
The Second World Symposium, Evian, 1998
On account of “remarkable progress in the field of pulmonary hypertension.”43 the second WHO
meeting was held in Evian in 199843. In addition to detailing the advances in the understanding of
the pathophysiology and therapeutic options, one of the key steps forward from this document
were the categorisation of all pulmonary hypertension into 5 groups, based on pathophysiology,
clinical presentation and treatments. There was the consequent abolition of the term ‘secondary’
pulmonary hypertension. These 5 groups have provided the framework for all subsequent
categorisations at the following WHO meetings. Another important definition for both clinical
and experimental use was the modification of the NYHA classification into the WHO functional
classification for pulmonary hypertension (Table 1).
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In 2001 the first randomised controlled trial of an oral agent to treat pulmonary hypertension was
published47. The agent was bosentan, an oral antagonist of both endothelin receptors A and B. The role
of endothelin in pulmonary hypertension has recently been reviewed in this journal48. It was tested in a
group of 32 patients with either primary or scleroderma-associated pulmonary hypertension. The primary
outcome of the study was a statistically significant difference in six-minute walk test distance compared
with placebo in severe pulmonary arterial hypertension. On the basis of this, the Bosentan Randomised
Trial of Endothelin Antagonist Therapy (BREATHE-1) was set up to investigate the effects on exercise
capacity in patients in WHO functional class III or IV49. The study took place across 27 centres in Europe,
North America, Israel and Australia and randomised 213 patients who were followed-up for 16 weeks.
The significant improvement in six-minute walk test was reproduced, although there was only a
mean difference of 44m between the bosentan and placebo arms. Importantly, however, there was
an improvement in WHO functional class in patients taking bosentan. On the basis of these studies,
the FDA licensed bosentan for patients in WHO functional classes III and IV in 2001.
At the time of the 2nd WHO meeting, inhaled NO had been noted as a potent and selective pulmonary
vasodilator andwasbeing used as a short-term treatment of pulmonary hypertension43. This pathway had
yet to be targeted by agents that could be used in an outpatient setting. Sildenafil, a phosphodiesterase
type 5 inhibitor, had been noted in a case series of infants to ameliorate the effects of inhaled NO
withdrawal, by preventing cyclic guanosine monophosphate (cGMP) degradation50. (NO increases
intracellular cGMP activity by soluble guanylate cyclase, which results in smooth muscle relaxation.)
Furthermore, one study found it to be as effective a pulmonary vasodilator as NO in the acute setting
in patients under consideration for heart-lung transplantation in WHO functional classes III and IV51.
The first published case report of the use of sildenafil in adults to treat pulmonary hypertension was in
2000 and showeda reduction in estimated pulmonary artery pressure on echocardiography in addition to
an increase in exercise capacity52. There was building evidence that sildenafil would be a useful therapy
in pulmonary hypertension, with a small randomised controlled trial of 22 patients in WHO functional
class II or III reporting a statistically significant improvement in exercise capacity as assessed by exercise
time on a treadmill53. However, at the time of the 3rd WHO meeting in Venice in 2004 the large Sildenafil
Use in Pulmonary Arterial Hypertension (SUPER-1) randomized controlled trial was still ongoing.
The SUPER-1 trial was undertaken across 53 centres internationally, randomising 278 patients from
WHO functional classes II, III and IV56. At 12 weeks there was significant improvement in six-minute
walk test distance compared with placebo that was not dose-dependant. The mean improvement from
baseline was 51m in 222 patients who completed 1 year of sildenafil monotherapy. Furthermore all the
doses reduced the mean pulmonary artery pressure and improved WHO functional class. The FDA
licensed sildenafil for use in all WHO functional classes in 2005.
The Third World Symposium, Venice, 2004
The 3rd WHOmeeting in 2004 refined the classification further and primary pulmonary hypertension,
as a term, was discarded in favour of idiopathic pulmonary arterial hypertension, as there are number
of conditions, such as connective tissue disease, anorexigen use, portal hypertension and HIV
infection that were similar to ‘primary’ pulmonary hypertension54. In view of importance of accurate
diagnosis, in terms of aetiology of pulmonary hypertension, and the availability of a few treatment
options, one of the major steps forward at the 3rd WHOmeeting was the development of a ‘treatment
algorithm’ for severe (WHO functional class III and IV) pulmonary hypertension55.
The Fourth World Symposium, Dana Point, 2008
The 4th WHO meeting took place in Dana Point in 200857. At the time, 20 randomised controlled
trials with 9 compounds had been completed, with 6 trials testing combinations of agents;
approximately 5000 patients had participated58. These studies allowed the creation of an
evidence-based treatment algorithm that now encompassed all WHO functional classes of
pulmonary arterial hypertension for the first time58. A second key area of discussion and advance
was the discussion about clinical trial design and the need for collaborative efforts across multiple
centres. Particular focus was given to relevant endpoints, in particular ‘time to clinical worsening’
that had been used in a number of randomised controlled trials with different definitions.
A standardised definition was developed59.
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Over the course of the 5 years between the 3rd and 4th WHOmeetings, 6 more agents were developed
and approved by the FDA: the prostacyclin analogues treprostinil and iloprost (beraprost was not
approved); the endothelin receptor antagonists sitaxentan (withdrawn in 2010 on account of fatal
liver failure) and ambrisentan; the phosphodiesterase-5 inhibitors sildenafil and tadalafil.
Since Dana Point in 2008, the FDA has approved two more agents, both in 2013. The first,
macitentan, was developed to improve the safety profile of the endothelin receptor antagonists,
particularly with regards to liver toxicity, in addition to efficacy. The Study with an Endothelin Receptor
Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) is the largest
single randomised controlled trial in pulmonary arterial hypertension to date with 742 patients
enrolled60. It found a significant reduction in a composite end-point of time to clinical worsening over a
median treatment period of 115 weeks. The study design was a direct response to the suggestions from
Dana Point and thus set a new standard for future trials.
The second is riociguat, an oral guanylate cyclase stimulator that acts on the NO pathway. It causes
vasodilatation by promoting cGMP activity through guanylate cyclase, rather than simply increasing
activity by preventing breakdown with phosphodiesterase 5 inhibitors. In the Pulmonary Arterial
Hypertension Soluble Guanylate Cyclase Stimulator Trial 1 (PATENT-1) there was a significant
improvement in the primary endpoint of six-minute walk test distance at 12 weeks61. Interestingly,
a similar benefit was also found in the Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Soluble Guanylate Cyclase Stimulator Trial 1 (CHEST-1) randomised controlled trial, which assessed
the role of riociguat in patients with CTEPH deemed unsuitable for pulmonary endarterectomy or
with residual pulmonary hypertension post pulmonary endarterectomy62.
This brings us to the latest WHO meeting which took place in 2013. Table 2 summarises all the
current licensed treatments. These all act via one of three pathways: the prostacyclin, endothelin
and nitric oxide pathways diagrammed in Figure 1.
There is currently a recently completed clinical trial, A Study of First-Line Ambrisentan and Tadalafil
Combination Therapy in Subjects with Pulmonary Arterial Hypertension (AMBITION) investigating the
role for up-front combination oral therapy at treatment initiation65. Although yet to be published, the
results were presented in the European Respiratory Congress in 2014. Combination therapy with
ambrisentan and tadalafil was found to reduce the risk of clinical failure by half, prolonging the time to
first clinical failure event (its primary endpoint).
Table 2. Currently licensed treatments in pulmonary arterial hypertension (adapted from Galie et al.,
2013)63.
Drug Key trials Year of FDA approval
Prostacyclin Pathway
Epoprostenol Barst et al. (1996) 1995
Iloprost AIR 2004
Treprostinil Simonneau et al. (2002) 2002
Endothelin Pathway
Bosentan BREATHE-1 2001
Ambrisentan ARIES-1 2007
ARIES-2
Macitentan SERAPHIN 2013
Nitric Oxide Pathway
Sildenafil SUPER-1 2005
Tadalafil PHIRST 2009
Riociguat PATENT-1 2013
The Fifth World Symposium, Nice, 2013
Both of the new agents, macitentan and riociguat, were incorporated into the treatment algorithm at
the 5th WHO meeting which took place in Nice in 201363. In addition to updated clinical
classifications (Table 3) and management algorithms across all types of pulmonary hypertension,
the meeting highlighted the deepening understanding of the complexity of pulmonary
hypertension: including the intertwining of inflammatory, proliferative and disordered metabolic
states64.
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Of the new agents currently in the drug development pipeline, selexipag is the most advanced.
It is a highly selective oral prostacyclin receptor agonist that has the potential to have an improved
safety profile compared to the prostacyclin analogues (which also act on gastrointestinal
prostaglandin receptors causing a number of side effects). Preliminary studies have shown that it
improves haemodynamics66 and so the phase III Prostaglandin Receptor Agonist in Pulmonary
Arterial Hypertension (GRIPHON) study has completed with preliminary results showing a
significant reduction in time to first event although comprehensive analysis is still ongoing67,68.
Figure 1. The three key pathways upon which currently licensed treatments for pulmonary arterial
hypertension act. The prostacyclin and nitric oxide pathways cause vasodilatation and the endothelin pathway
vasoconstriction. Dashed lines indicate omitted steps. Enzymes are coloured green. Therapies are coloured red.
Lines ending in a triangle indicate an agonist/potentiator, lines ending in a bar indicate an antagonist/inhibitor.
Abbreviations: AC, adenylate cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate
(AMP); cGMP, cyclic guanosine monophosphate (GMP); ECE, endothelin converting enzyme; eNOS, endothelial
nitric oxide synthase; ERA, endothelin receptor antagonist; ET-1, endothelin; ETA, endothelin receptor type A;
GTP, guanosine triphosphate; IP, prostaglandin I2 receptor; IP3, inositol triphosphate; PDE5I, phosphodiestase
(PDE) type 5 inhibitor; PGI2, prostaglandin I2; PGIS, prostaglandin I synthase; PIP2, phosphatidylinositol
bisphosphate; PLC, phospholipase C; NO, nitric oxide; sGCS, soluble guanylate cyclase (sGC) stimulator.
Adapted from Montani et al. (2014)92.
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With our increasing understanding of the vascular biology in pulmonary hypertension, vasoactive
targets outside of the three currently targeted pathways are being increasingly studied. The Rho
signalling pathway has been shown to have effects on vasoconstriction and cell proliferation.
Simvastatin, which is an indirect inhibitor of Rho kinase, was found not to be of prolonged benefit in
reducing right ventricular mass when added to targeted therapy in a clinical trial of 42 patients69.
However, fasudil, a direct Rho-kinase inhibitor, has been shown to improve pulmonary
haemodynamics70,71, and is the most promising of the agents targeting novel vasoactive pathways, but
further studies are needed to assess its effect on clinical outcomes. Interestingly, the potential effects
on cell proliferation highlight the widening reach of putative new therapies beyond simple
vasodilatation and the need to focus on vascular remodelling.
THE FOURTH AGE: GENETICS, THE METABOLIC THEORY AND THE FUTURE
It was known since the 1950s that familial cases of pulmonary hypertension existed73,74. In the
1981 registry, 6% of patients reported a family history of pulmonary hypertension2. Analysis of
pedigrees suggested an autosomal dominant pattern of inheritance72. With the advent of genetic
sequencing, mapping was undertaken in families to identify the causes of hereditary pulmonary arterial
hypertension and help inform pulmonary hypertension pathology as a whole. Mutations in the gene
encoding bone morphogenetic protein receptor 2 (BMPR2), a member of the transforming growth
factor-beta (TGF-b) family signalling pathway, were identified as causing heritable pulmonary arterial
hypertension in 2000 by two independent groups73,74. Over 300 BMPR2 mutations have now been
identified, accounting for 75% of patients with heritable pulmonary arterial hypertension75. They have
also been identified in 25% of patients with idiopathic pulmonary hypertension75. As a result of this,
the role of BMPR2 signalling has been extensively investigated in pulmonary arterial hypertension76.
A number of mutations in other genes have also been identified: ALK-1, SMAD9 and ENG also from
the TGF-b family and CAV1 and KCNK3 which are not75.
Table 3. Updated Nice 2013 classification of pulmonary hypertension (from Simonneau et al.,
2013)93.
1 Pulmonary arterial hypertension
1.1 Idiopathic PAH
1.2 Heritable PAH
1.2.1 BMPR2
1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3
1.2.3 Unknown
1.3 Drug and toxin induced
1.4 Associated PAH
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis
10 Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis
100 Persistent pulmonary hypertension of the newborn
2 Pulmonary hypertension due to left heart disease
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
3 Pulmonary hypertension due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental lung diseases
4 Chronic thromboembolic pulmonary hypertension
5 Pulmonary hypertension with unclear multifactorial mechanisms
5.1 Haematological disorders: chronic haemolytic anaemia, myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental pulmonary hypertension
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However, only 20% of people with BMPR2 mutations go on to develop pulmonary hypertension77
suggesting that there are other factors that contribute to the development of disease. There is
increasing evidence that inflammation and altered immunity provides a ‘second-hit’78. Another ‘hit’
may occur via epigenetic mechanisms, such as DNA methylation, histone modification and the action
of microRNAs79 which in turn may be influenced by environmental factors, inflammation/infection,
hormones or exposure to drugs The latest “metabolic theory” also proposes a central role for altered
mitochondrial metabolism, promoting a switch away from glucose oxidation towards cytolsolic
glycolysis and fatty acid oxidation (similar to cancer biology) which, in turn, sets a pro-proliferative,
apoptosis-resistant phenotype80. There is now a race to synthesise a unifying theory to link genetic
pre-disposition with inflammation and dysregulated metabolic function. Although out of the
scope of this article the reader is directed to the excellent reviews on these subjects produced at
the 5th WHO Meeting64,75.
With this advance in our understanding of cell proliferation, genetics, dysregulated metabolism and
inflammation in PAH, trials of new treatments targeting these abnormalities are underway, although
none have yet been licensed.
Perhaps the most extensively studied are the tyrosine kinase inhibitors, which inhibit platelet derived
growth factor (PDGF). PDGF signalling is important in the vascular smooth muscle proliferation
associated with PAH. Imatinib is a tyrosine kinase inhibitor that has been licensed for a number of
years for the treatment of chronic myeloid leukaemia targeting the bcr-abl tyrosine kinase. It is also an
inhibitor of the PDGF pathway. The Imatinib in Pulmonary Arterial Hypertension, a Randomised Efficacy
Study (IMPRES) phase III trial found that there was a significant improvement in the primary endpoint of
exercise capacity as assessed by the six-minute walk test, but that serious adverse events and
discontinuations were common81. As a result of this its licensing application has been recently
withdrawn82. A subsequent trial of Nilotinib, another tyrosine kinase inhibitor, has also been stopped
early due to a high rate of serious adverse cardiac events83. While the rationale behind the use of
tyrosine kinase inhibitors in PAH is sound, porting agents that have been designed for use in chronic
myeloid leukaemia to pulmonary hypertension has not delivered tolerable safety profiles in
this disease.
Current clinical trials also include agents that are building on our understanding of the genetics to
promote BMP signalling, such as tacrolimus84 and our understanding of metabolic dysregulation to
prevent the shift to glycolysis and promote mitochondrial metabolism, such as dichloroacetate85. There
are also case reports of using agents to target key inflammatory cytokines in pulmonary hypertension,
such as tocilizumab, an anti-IL-6 monoclonal antibody licensed in rheumatoid arthritis86–88.
Figure 2. A timeline of key milestones in the history of pulmonary arterial hypertension. * Date of Food and Drug
Administration approval. Abbreviations: BMPR2, bone morphogenetic protein receptor type 2; PAH, pulmonary
arterial hypertension; PH, pulmonary hypertension; RCT, randomised controlled trial; WHO, World Health
Organisation.
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CONCLUSION
Our journey, represented as a timeline in Figure 2, has taken us from the first pathological descriptions
of PAH, via the physiological measurements of the effects of PAH to the subsequent development
of pharmacological agents that can improve pulmonary haemodynamics and survival. More recent
understanding of the complex processes that underlie the disease have led us to consider a number
of alternative targets for therapeutic agents. Whilst much progress has been made since the first
descriptions in the 19th century, there is still much more progress that needs to happen in the
21st century.
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